NCT04891068View on ClinicalTrials.gov

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Breast Cancer FemaleBreast Cancer Invasive
Interventions
DRUG

Azacitidine

5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5

Trial Locations (1)

60612

RECRUITING

University of Illinois Cancer Center, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER